1 1

1

2 2

2

Recommended Products

About Us

Xinxiang Kangmin Hygienic Materials Development CO.,LTD.

Xinxiang Kangmin Hygienic Materials Development CO.,LTD,Established in the Central Plains of China, with convenient transportation. Kangmin Group is an innovative enterprise specializing in the production and development of medical consumables. Kangmin Group was established in 1998 and covers an area of 46,000 square meters. The company currently has more than 200 advanced production equipment (sets), with a degree of mechanization accounting for more than 90%.Strong production capacity is the embodiment of strength and delivery speed.Kangmin Group's existing main products include non-woven fabric series, polymer series, medical auxiliary bag series, protection and nursing series, cotton yarn series, cotton swabs, cotton ball series, glove series, compressed towels and other products.

About Us

Products

Non-woven fabric series

Non-woven fabric series

Medical auxiliary package

Medical auxiliary package

Cotton yarn series

Cotton yarn series

Cotton swab

Cotton swab

Glove series

Glove series

Protection

Protection

Non-woven fabric series

Non-woven fabric series

Cotton yarn series

Cotton yarn series

Glove series

Glove series

Medical auxiliary package

Medical auxiliary package

Cotton swab

Cotton swab

Protection

Protection

Committed to the production of medical equipment
and medical sanitary materials for 20 years

  • 20

    +

    Focus on medical devices

  • 200

    +

    Production Equipment

  • 46000

    +

    Area

Company Philosophy

Establish corporate image

Establish corporate image

The company takes "Health and Health for the people's health" as its mission and makes unremitting efforts. The company organizes production in strict accordance with 

Continuously create market demand

Continuously create market demand

Kangmin Eisai ensures that the quality of its products meets the requirements of national and industrial standards. Has won the general trust of users. We provide high-quality 

Exquisite craftsmanship

Exquisite craftsmanship

The company currently has more than 200 advanced production equipment (sets), with a degree of mechanization accounting for more than 90%, ensuring the company's 

News​  

Our company has obtained TUV Rheinland CE certificate
2021-01-27
Our company has obtained TUV Rheinland CE certificate
Kangmin Group, for the health of the people. Since its establishment, our company
See more information
Kangmin Group, for the health of the people. Since its establishment, our company
Changyuan City Federation of Trade Unions awarded our company (Kangmin Eisai) the "Model Home of Workers" and the four-star "Grassroots Vigor Union"
2020-07-30
Changyuan City Federation of Trade Unions awarded our company (Kangmin Eisai) the "Model Home of Workers" and the four-star "Grassroots Vigor Union"
On July 29, 2020, a representative of the Municipal Federation of Trade Unions made a special trip to our company to award the license, and awarded our company the "employee model home" and the four-star "grass-roots vitality union". Our company ( Kangmin Eisai ) Manager Liu accepted on behalf of the company Medals.
See more information
On July 29, 2020, a representative of the Municipal Federation of Trade Unions made a special trip to our company to award the license, and awarded our company the "employee model home" and the four-star "grass-roots vitality union". Our company ( Kangmin Eisai ) Manager Liu accepted on behalf of the company Medals.
500 million anti-allergic drugs welcome reviewers again 4.9 billion market only 3 varieties have been reviewed
2019-04-13
500 million anti-allergic drugs welcome reviewers again 4.9 billion market only 3 varieties have been reviewed
On November 24, the domestic market application of AstraZeneca’s PD-L1 Durvalumab injection ( Imfinzi ) was under “approval” status. It is expected that it will soon be approved as the first domestically marketed PD-L1 monoclonal antibody drug for Treatment of inoperable stage III non-small cell lung cancer.
See more information
On November 24, the domestic market application of AstraZeneca’s PD-L1 Durvalumab injection ( Imfinzi ) was under “approval” status. It is expected that it will soon be approved as the first domestically marketed PD-L1 monoclonal antibody drug for Treatment of inoperable stage III non-small cell lung cancer.

CONTACT INFORMATION

Add:Dingluan Industrial Zone, Changyuan City, Henan Province  
International Division Add:Pilot Free Trade Zone in Zhengzhou City, Henan Province, Lvdi Xinduhui,Building 9 

ONLINE MESSAGE

Username used for comment:
Feedback of customer
Description:
验证码

Copyright ©Xinxiang Kangmin Hygienic Materials Development CO.,LTD.    豫ICP备16017456号    Powered by: www.300.cn